Highlights
• Allergy Therapeutics proposes cancelling its AIM admission and re-registering as a private Limited Company next year.
• Shareholders will vote on the proposals at the Annual General Meeting scheduled for 14 December 2026.
• If approved, cancellation would take effect at 7:00am on 22 December 2026 under the published timetable.
• A matched-bargain Facility would run for at least 12 months, carrying a 1.5% trading fee.
For anyone holding shares in Allergy Therapeutics (LSE:AGY), the coming weeks bring a decision point. The company has proposed cancelling the admission of its shares to trading on AIM and re-registering as a private limited company, a change that would alter how the shares are held and traded. Here is what the proposal involves, why it has been put forward and how the timetable runs.
Why the Company Is Proposing to Leave AIM
The company cites two main reasons for the proposal.
The first is cost. Maintaining the AIM admission costs more than £1m a year.
The second is liquidity. The free float stands at about 9% of the shares, and average daily trading Volume is about 444,544 shares, which Allergy Therapeutics (LSE:AGY) puts at about 0.01% of issued share capital. Taken together, cost and Liquidity form the reasons the company gives for seeking to leave the market.
The Shareholder Vote
The proposals require shareholder approval and will be put to the annual general meeting on 14 December 2026. The announcement does not disclose the approval threshold that applies.
SkyGem and Southern Fox together hold 87.98% of the shares. Both have committed to vote in favour of the proposals.
The directors hold 9,167,707 shares, representing about 0.14% of the shares in issue.
Key Dates
The timetable set out by the company runs as follows:
• 14 December 2026: annual general meeting and shareholder vote
• 22 December 2026, 7:00am: cancellation of AIM admission expected to take effect
• Week commencing 11 January 2027: re-registration as a private limited company expected
The cancellation and re-registration both depend on the proposals being approved at the AGM.
Trading After Cancellation
Once the shares leave AIM, Allergy Therapeutics (LSE:AGY) plans to provide a matched-bargain facility to give shareholders a way to buy or sell shares. The facility is intended to run for a minimum of 12 months.
Trades through the facility would carry a fee of 1.5%.
Understanding the Proposal
The company proposes to cancel the admission of its shares to trading on AIM and to re-register as a private limited company. AIM is the London Stock Exchange's market for smaller growth companies, and cancelling admission means the shares would no longer be traded there. The company gives two reasons: the cost of maintaining the admission, which is more than £1m a year, and liquidity, with a free float of about 9% and Average Daily Volume of about 444,544 shares, which it puts at about 0.01% of issued share capital.
The Vote and the Shareholdings
The proposals require shareholder approval at the annual general meeting on 14 December 2026. SkyGem and Southern Fox together hold 87.98% of the shares, and both have committed to vote in favour. The directors hold 9,167,707 shares, about 0.14% of the shares in issue. The announcement does not disclose the approval threshold that applies, so readers will look to the notice of meeting for that detail. Both the cancellation and the re-registration depend on the proposals being approved at the meeting.
What Happens to Trading
Once the shares leave AIM, the company plans to provide a matched-bargain facility, which is a service that matches buyers and sellers of shares in a company that is no longer traded on a market. The facility is intended to run for a minimum of 12 months, and trades through it would carry a fee of 1.5%. A matched-bargain facility works differently from a stock market because a trade takes place only when a buyer and seller are matched, so shareholders may wish to consider how that affects the timing of any sale. For readers following Allergy Therapeutics, the timetable, the meeting date and the terms of the facility are the main practical points in the announcement.






Please wait processing your request...